Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 12, Issue 10, 2016, Pages 1047-1057

  Iwata, Shigeru ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

B cell; dendritic cell; JAK inhibitors; RA; T cell

Indexed keywords

BARICITINIB; DECERNOTINIB; FILGOTINIB; ITACITINIB; JANUS KINASE; JANUS KINASE INHIBITOR; PEFICITINIB; RUXOLITINIB; TOFACITINIB; UPADACITINIB; 2-((2-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YL)AMINO)-2-METHYL-N-(2,2,2-TRIFLUOROETHYL)BUTANAMIDE; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; JANUS KINASE 1; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE; VALINE;

DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; CLINICAL TRIALS AS TOPIC; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; JANUS KINASE 1; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME; VALINE;

EID: 84988036902     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1080/1744666X.2016.1189826     Document Type: Review

References (66)

1. D.L.Scott, F.Wolfe, T.W.Huizinga Rheumatoid arthritis. Lancet. 2010;25:1094–1108.
2. G.R.Burmester, A.J.Kivitz, H.Kupper, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab:the randomised CONCERTO trial. Ann Rheum Dis. 2015;74:1037–1044.
3. D.E.Furst, P.Emery. Rheumatoid arthritis pathophysiology:update on emerging cytokine and cytokine-associated cell targets. Rheumatology. 2014;53:1560–1569.
4. I.B.McInnes, G.Schett. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–2219.
5. Y.Tanaka. Next stage of RA treatment:is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(Suppl 2):ii124–7.
6. J.S.Smolen, D.Aletaha, J.W.Bijlsma, et al. Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis. 2010;69:631–637.
7. T.Hunter. The age of crosstalk:phosphorylation, ubiquitination, and beyond. Mol Cell. 2007;28:730–738.
8. X.Min, D.Ungureanu, S.Maxwell, et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (Tyk2). J Biol Chem. 2015;290:27261–27270.
9. H.M.Hammarén, D.Ungureanu, J.Grisouard, et al. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015;112:4642–4647.
10. J.J.Babon, I.S.Lucet, J.M.Murphy, et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462:1–13.
11. J.A.Johnston, M.Kawamura, R.A.Kirken, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994;370:151–153.
12. S.M.Russell, N.Tayebi, H.Nakajima, et al. Mutation of Jak3 in a patient with SCID:essential role of Jak3 in lymphoid development. Science. 1995;270:797–800.
13. T.Nosaka, J.M.Van Deursen, R.A.Tripp, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270:800–802.
14. S.M.Russell, J.A.Johnston, M.Noguchi, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3:implications for XSCID and XCID. Science. 1994;266:1042–1045.
15. L.D.Notarangelo, P.Mella, A.Jones, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat. 2001;18:255–263.
16. J.G.Walker, M.J.Ahern, M.Coleman, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006;65:1558–1564.
17. J.G.Walker, M.J.Ahern, M.Coleman, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis:unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006;65:149–156.
18. J.C.Venter, M.D.Adams, E.W.Myers, et al. The sequence of the human genome. Science. 2001;291:1304–1351.
19. P.S.Changelian, M.E.Flanagan, D.J.Ball, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–8.• First published on efficacy of tofacitinib.
20. B.Bodenmiller, E.R.Zunder, R.Finck, et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012;30:858–867.
21. + T cells. Arthritis Rheum. 2012;64:1790–1798.
22. G.Vahedi, Y.Kanno, Y.Furumoto, et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature. 2015;520:558–562.
23. S.Kubo, K.Yamaoka, M.Kondo, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192–2198.
24. J.G.Walker, M.J.Ahern, M.Coleman, et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:992–999.
25. S.P.Wang, S.Iwata, S.Nakayamada, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014;73:2213–2215.
26. M.Onda, K.Ghoreschi, S.Steward-Tharp, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014;193:48–55.
27. A.Yarilina, K.Xu, C.Chan, et al. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012;64:3856–3866.
28. S.Rosengren, M.Corr, G.S.Firestein, et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes:autocrine role of type I interferon. Ann Rheum Dis. 2011;71:440–447.
29. D.L.Boyle, N.Wei, A.K.Singhal, et al. The JAK inhibitor tofacitinib suppresses synovial jak1-stat1 signalling in rheumatoid arthritis. Ann Rheum Dis. 2013;72:138.
30. P.S.Changelian, M.E.Flanagan, D.J.Ball, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–878.
31. D.C.Borie, M.J.Larson, M.G.Flores, et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation. 2005;80:1756–1764.
32. G.Rousvoal, M.S.Si, M.Lau, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int. 2006;19:1014–1021.
33. K.Ghoreschi, M.I.Jesson, X.Li, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP- 690,550). J Immunol. 2011;186:4234–4243.
34. Y.Tanaka, M.Suzuki, H.Nakamura, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63:1150–1158.
35. J.M.Kremer, B.J.Bloom, F.C.Breedveld, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis:results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895–1905.
36. R.Fleischmann, M.Cutolo, M.C.Genovese, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–629.
37. J.M.Kremer, S.Cohen, B.E.Wilkinson, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970–981.
38. R.Fleischmann, J.Kremer, J.Cush, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.(Oral-Solo).
39. G.R.Burmester, R.Blanco, C.Charles-Schoeman, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors:a randomised phase 3 trial. Lancet. 2013;381:451–60.(Oral-Step).
40. R.F.Van Vollenhoven, R.Fleischmann, S.Cohen, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.(Oral-Standard).
41. J.Kremer, Z.G.Li, S.Hall, et al. Tofacitinib in combination with nonbiologic disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis:a randomized trial. Ann Intern Med. 2013;159:253–61.(Oral-Sync).
42. D.Van Der Heijde, Y.Tanaka, R.Fleischmann, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate:twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.(oral-scan).
43. K.Sonomoto, K.Yamaoka, S.Kubo, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis:relation to efficacy and infectious adverse events. Rheumatology. 2014;53:914–918.
44. J.S.Fridman, P.A.Scherle, R.Collins, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis:preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
45. Y.Tanaka, K.Emoto, Z.Cai, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy:a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016 Feb 1;43:504–511. pii:jrheum.150613. [Epub ahead of print]
46. R.Fleischmann, T.Takeuchi, E.Douglas Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs):phase 3 trial results. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER:1045
47. P.C.Taylor, E.C.Keystone, D.Van Der Heijde, et al. Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis (RA) and an inadequate response to background methotrexate therapy:results of a phase 3 study. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER:2L.
48. M.C.Genovese, J.M.Kremer, O.Zamani, et al. Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors:results of the Phase 3 RA-BEACON study [abstract OP0029]. Ann Rheum Dis. 2015;74(Suppl. 2):75–76.
49. M.C.Genovese, J.M.Kremer, C.Kartman, et al. Previous biologic disease-modifying antirheumatic drug (bDMARD) exposure and efficacy and safety analysis from a phase 3 study of baricitinib in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitors. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER:1046.• Efficacy of baricitinib in RA patients with inadequate response to biologics.
50. L.Van Rompaey, R.Galien, E.M.Van Der Aar, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–3577.
51. A.Kavanaugh, L.Ponce, R.Cseuz, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective as monotherapy in patients with active rheumatoid arthritis:results from a phase 2B dose ranging study. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER:1049.
52. R.Westhovens, R.Alten, D.Pavlova, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis:results from a phase 2B dose ranging study. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER:1048
53. T.Hoock, J.Hogan, S.Mahajan, et al. VX-509, an orally available Janus kinase 3 (JAK3) specific inhibitor, showed robust activity in pre-clinical models of aberrant immune/inflammatory function. Arthritis Rheum. 2011;63:S443.
54. M.C.Genovese, R.F.Van Vollenhoven, C.Pacheco-Tena, et al. VX-509 (Decernotinib), an oral selective JAK-3 Inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46–55.
55. S.Yamazaki, M.Inamia, M.Ito, et al. ASP015K:a novel JAK inhibitor demonstrated potent efficacy in adjuvant-induced arthritis model in rats. Arthritis Rheum. 2012;64:S882.
56. T.Takeuchi, Y.Tanaka, M.Iwasaki, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan:a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057–1064.
57. Voss JW, Camp HS, Padley RJ. JAK1 selective inhibitor and uses thereof WO2015061665A1.
58. J.M.Kremer, E.C.Keystone, P.Emery, et al. Safety and efficacy of ABT-494, a novel selective JAK1 Inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. ACR/ARHP Annual Meeting; 2015. ABSTRACT NUMBER:14L.
59. M.Luchi, R.K.Fidelus-Gort, D.Douglas, et al. A randomized, dose-ranging, placebo-controlled 84-day (12-week) study of INCB039110, a selective Janus kinase-1 inhibitor in patients with active rheumatoid arthritis. Arthritis Rheum. 2013;65(Suppl 10):1797.
60. M.Luchi, R.Fidelus-Gort, D.Douglas, et al. A randomized, dose-ranging, placebo-controlled, 84-day study of INCB039110, a selective Janus kinase-1 inhibitor, in patients with active rheumatoid arthritis. ACR/ARHP Annual Meeting; 2013. ABSTRACT NUMBER:1797.
61. W.V.Williams, P.Scherle, J.Shi, et al. Initial efficacy of INCB018424, a selective Janus kinase 1& 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). EULAR; 2008. abstract OP-0044.
62. K.L.Winthrop, H.Valdez, E.Mortensen, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:S1051.
63. D.Mittal, M.M.Gubin, R.D.Schreiber, et al. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
64. J.Wollenhaupt, J.Silverfield, E.B.Lee, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. J Rheumatol. 2014;41:837–852.
65. J.R.Curtis, E.B.Lee, I.V.Kaplan, et al. Tofacitinib, an oral Janus kinase inhibitor:analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75:831–841.
66. F.Vincenti, H.T.Silva, S.Busque, et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J Transplant. 2015;15:1644–1653.